ClinicalTrials.gg
RecruitingNCT06847282MOVE PedsUpdated Feb 25, 2026

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

An observational study in Muscular Dystrophy, Facioscapulohumeral, sponsored by University of Kansas Medical Center. Recruiting at 7 sites in 2 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by University of Kansas Medical Center · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
7th of 11
80 · median 94
Started
2025
with 4 others
Observational
11 of 32
4 open now
Primary completion
2027-05
later than 0 of 12 live
Registered
26th of 32
by date
Lead sponsor
3 of 32
University of Kansas Medical Center

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2025, is one of 11 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 26th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

The primary goal of this study is to validate motor and functional outcomes and refine clinical trial strategies for pediatric-onset FSHD

Read the detailed description

MOVE Peds is a prospective 2-year study recruiting eighty pediatric participants to accelerate therapeutic development for pediatric-onset FSHD. The study aims to validate outcomes and refine clinical trial strategies. Previous cross-sectional studies suggest that younger age of onset is linked to greater clinical severity and that having 1-3 D4Z4 repeats is associated with extra-muscular complications in pediatric FSHD.

Prospective studies in early-onset FSHD have been limited by the small number of sites and low recruitment and follow-up rates. Early-onset pediatric FSHD is of high interest to drug companies because:

  1. It results in a more significant disease burden than in adults.
  2. Treating FSHD at earlier ages may have a more lasting and profound effect.
  3. Genetic, molecular, and clinical factors may differ between pediatric and adult-onset FSHD.
  4. Smaller body size and faster progression rates may make AAV-delivered gene therapies more feasible.

The FSHD CTRN's previous research showed that the FSHD composite functional measure (FSHD-COM), reachable workspace (RWS), and quantitative MRI measures (qMRI) are responsive to disease progression or treatment in adults with FSHD and correlate with performance. Investigators hypothesize that early changes in qMRI in pediatric subjects will predict 2-year changes in FSHD-COM Peds or RWS.

03

Conditions studied

  • Muscular Dystrophy, Facioscapulohumeral

Keywords

  • FSHD
  • Pediatric
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study is meant to target children most likely to be included in clinical trials: children who are clinically affected, old enough to perform functional measures, and still ambulatory. On outcomes proposed for MOVE Peds they would have room to show progression or improvement and be at a stage ideal to assess potential inclusion criteria: in particular whether symptom onset age or genetics separate early-onset from other childhood onset FSHD, or whether they exist on a spectrum of severities. At least half will qualify as early-onset (facial weakness before age 5 and shoulder weakness before age 10 or symptom onset before age 18 and 1-3 D4Z4 repeats). We will be also looking at a small cohort of early onset participants who's ambulation has been affected or is no longer able to ambulate. this will help us assess all child progression and understand the connection of early-onset and ambulation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5-17 years.
  • Genetically confirmed FSHD (types 1 or 2).
  • Symptomatic weakness (facial, shoulder, core, or limb weakness)
  • Able to complete a 10-meter walk without the support of another person in less than 12 seconds (canes, walking sticks, and braces allowed; no walker). In order to include early onset participants up to 8 individuals will be entered with baseline 10MWR > 12 seconds or who are no longer ambulatory (≤10%)

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to provide or assent. Any other medical condition which in the opinion of the investigator would interfere with study participation.
  • with ongoing treatment with chemotherapeutic agents or anabolic agents
  • Use of including prednisone or performance enhancing drugs including testosterone within 6 months
  • Pregnancy
  • Recent or ongoing infection
  • Presence of to performance of MRI: pacemaker, metallic foreign body in eye, brain aneurysm clip (unless documented as MRI compatible)
  • In the opinion of the investigator unable to follow directions for standardized testing

    • Note: Not being able to complete MRI will not result in a screen failure. If subject is not able to complete the procedure due to fear or anxiety, they will have the opportunity to try again at later visits. However, Subject must be willing to attempt to perform the MRI to meet inclusion/exclusion criteria
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort One

    Cohort One will be individuals who are able to complete the 10 meter walk/run test in less than twelve seconds

  • Cohort Two

    cohort two will be individuals who complete the 10 meter walk/run test in more than 12 seconds or is no longer able to complete.

06

What researchers measure

Primary outcomes

  1. Pediatric FSHD-COM

    Investigators will collect the FSH-Composite outcome measure for children and adolescents. This measure assesses multiple body regions identified as important by patients, including leg function, shoulder and arm function, trunk function, hand function, and functional balance. The FSHD-COM Peds has been modified to include lighter weights for shoulder abduction and flexion, as well as elbow flexion, to accommodate the motor development and lower strength levels seen in children. Although the FSHD-COM Peds involves different measurements for each body region, these measurements are combined to produce a single composite score. The total score for the FSHD-COM Peds is out of 84, representing one comprehensive outcome measure

    Time frame: Baseline-2 years

  2. Reachable Work Space

    Subjects are seated in front of a stereo-camera and perform a standardized upper extremity movement protocol under the supervision of a study clinical evaluator. Five-hundred-gram wrist weights will be added. The standardized simple set of movements consist of lifting the arm from the resting position to above the head while keeping the elbow extended, performing the same movement in vertical planes at around 0, 45, 90, 135 degrees. The second set of movements consists of horizontal sweeps at the level of the umbilicus and shoulder.

    Time frame: Baseline-2 years

Secondary outcomes

  1. Quantitative MRI (qMRI) Fat Fraction %

    quantitative MRI measurements are considered gold standard for lean muscle volume measurement and disease biomarkers (fat volumes, fat faction, and STIR+ presence) that may be modulated by treatment. Muscle fat replacement and free-water hyperintensity indicate early disease changes before functional performance is affected. Muscles with an intermediate fat fraction (10-55%) predict disease progression over 1-2 years. Investigators will use a whole-body MRI and will find the fat fraction % in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period

    Time frame: Baseline-2 years

  2. Quantitative MRI (qMRI) Lean Muscle Volume (mL)

    Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers (fat volumes vs. lean muscle volumes and STIR+ presence) that may be modulated by treatment. Muscle fat replacement and free-water hyperintensity indicate early disease changes before functional performance is affected. Muscles with low lean muscle volume and an intermediate fat fraction (10-55%) predict disease progression over 1-2 years. Investigators will use whole-body MRI to measure lean muscle volume (mL) in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period.

    Time frame: Baseline-2 years

  3. Quantitative MRI (qMRI) Total Volume

    Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers (fat volumes, fat fraction and STIR+ presence) that may be modulated by treatment. The use of MRI has shown as a technique to predict disease progression. Investigators will use whole-body MRI to measure total volume (mL) in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period. This refers to the overall volume of a specific tissue or organ measured in milliliters (mL) using MRI.

    Time frame: Baseline-2 years

  4. Quantitative MRI (qMRI) STIR+ ( %)

    Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers, such as the percentage of lean muscle volume with Short Tau Inversion Recovery (STIR) enhancement. STIR MRI helps predict disease progression by highlighting areas of inflammation and edema within muscle tissue. This provides valuable insights into underlying disease processes, aiding in the prediction of progression and guiding treatment decisions. Investigators will use whole-body MRI to measure STIR positivity, indicating inflammation and edema, in pediatric subjects. These measurements will be compared with other factors to create a composite score over a two-year period.

    Time frame: Baseline-2 years

Other outcomes

  1. PROMIS Pediatric physical activity questionnaire (8 questions)

    an instrument developed by the NIH PROMIS initiative. It generates scores for physical function and the impact of physical limitations on daily life. Participants will answer questions about how often they engage in physical activity, ranging from 0 days to 6-7 days per week. Higher scores indicate greater levels of physical activity.

    Time frame: Baseline-2 years

  2. Neuro Qol Fatigue Scale

    assess the impact of fatigue on individuals with neurological conditions, measuring their severity, frequency, and effects on daily activities and quality of life using a 5- point rating system (1 being never and 5 being always).

    Time frame: Baseline-2 years

  3. The Facial Disability Index (FDI) physical score

    is a 5-item questionnaire which assesses the physical impact of facial weakness. The responses (graded 1-5, 5 being no difficulty and 1 being unable to do) are summed to create a total score, which is then converted into a percentage scale. A score of 100% represents normal function, while lower scores indicate increasing levels of disability.

    Time frame: Baseline-2 years

  4. ACTIVLIM

    measures how well people with neuromuscular disorders can perform daily activities. It includes 22 questions about tasks such as dressing, bathing, and walking, with difficulty rated as impossible, difficult, or easy.

    Time frame: Baseline-2 years

  5. Strength and Difficulties Questionnaire (SDQ)

    is a tool used to screen for emotional and behavioral problems in children and adolescents aged 2 to 17. It consists of 25 questions divided into five categories: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior. Each item is rated on a 3-point scale (0= not true, 1 = somewhat true and 2 = certainly true)

    Time frame: Baseline-2 years

  6. Patient Global Impression of Severity (PGI-S)

    Is a rating scale that patients can use to measure how severe they feel their symptoms are. Patients rate their condition on a scale from 1 (Normal) to 4 (Severe). This will serve as one of the study anchors.

    Time frame: Baseline-2 years

  7. Domain Delta

    is an instrument developed to assess quality of life and how disease has changed since last visit. the purpose of the "domain-delta" questionnaire is to determine each patient's perceived change in their health-related quality-of-life in the last 6-months. This questionnaire will inquire about total health as well as health related to 14 subdomains self-identified as important by patients during development of the FSHD Health Index. Participants indicate their perceived change by answering if an area "is a lot worse", "is a little worse", "there has been no change", "it is a little better", or "it is a lot better" for each subdomain. This will serve as one of the other anchors in the study.

    Time frame: Baseline-2 years

  8. North Star Assessment for Dysferlinopathy (NSAD)

    a tool used by clinicians to evaluate motor abilities in individuals with dysferlinopathy, a type of muscular dystrophy. It measures how well patients can perform various physical tasks, helping to track the progression of the disease. This assessment is useful for both walking and non-walking patients, providing important information to guide treatment and care plans. This will be used in comparison to how well the FSHD-COM Peds assessing subjects

    Time frame: Baseline-2 years

  9. Performance of Upper Limb (PUL)

    an assessment tool used to evaluate upper limb function in individuals with muscular dystrophies, such as Duchenne muscular dystrophy. It measures the ability to perform various motor tasks, providing insights into the strength and mobility of the arms and hands. The PUL helps track disease progression and guides treatment decisions by capturing detailed information about upper limb capabilities. This will be helpful in assessing Cohort two as well as will be utilized to the FSHD-COM Peds and RWS.

    Time frame: Baseline-2 years

  10. 100-Meter Walk/Run Test

    is a fixed-distance assessment used to measure an individual's maximum ambulatory ability. Participants are asked to walk or run 100 meters as quickly as they can, depending on their capability. This test is commonly used in research to evaluate physical performance and mobility, particularly in individuals with conditions affecting their walking ability. It helps researchers track changes in mobility over time and assess the effectiveness of interventions aimed at improving walking speed and endurance

    Time frame: Baseline-2 years

  11. Neuro Qol Pain Scale

    assess the impact of pain on individuals with neurological conditions, measuring their severity, frequency, and effects on daily activities and quality of life using a 5- point rating system (1 being never and 5 being always).

    Time frame: Baseline-2 years

  12. Patient Global Impression of Change (PGI-C)

    Is a rating scale that patients can use to measure if any change in severity has occurred since being in the study. patient rate their change on a scale from 1 to 7 (1 being no change or worse and 7 being a great deal better or improvement that has made all the difference). This will serve as one of the study anchors.

    Time frame: Baseline-2 years

07

Study locations

4 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Feb 26, 2025
StartActual
May 22, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847282
Responsible party
Jeffrey Statland (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Feb 26, 2025
Start date
May 22, 2025
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Michaela Walker, MPH
Contact
mwalker20@kumc.edu
913-945-9920
Rebecca Clay, BS
Contact
rclay@kumc.edu
9139459936
Jeffrey Statland, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion